Cargando…

Affinity maturation pathway of an anti-MPER neutralizing mAb, CAP206-CH12

Detalles Bibliográficos
Autores principales:	Tumba, NL, Gray, ES, Lambson, BE, Karim, SS Abdool, Liao, H, Haynes, BF, Alam, M, Morris, L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442096/ http://dx.doi.org/10.1186/1742-4690-9-S2-P65

Ejemplares similares

Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies
por: Scheepers, Cathrine, et al.
Publicado: (2022)

Generation of recombinant mAbs to vaccinia virus displaying high affinity and potent neutralization
por: Noy-Porat, Tal, et al.
Publicado: (2023)

P04-44. Generation of antibody responses to HIV-1 membrane proximal external region (MPER) antigen
por: Holl, TM, et al.
Publicado: (2009)

Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8
por: Soto, Cinque, et al.
Publicado: (2016)

SEPPA-mAb: spatial epitope prediction of protein antigens for mAbs
por: Qiu, Tianyi, et al.
Publicado: (2023)

A new approach to quantification of mAb aggregates using peptide affinity probes
por: Cheung, Crystal S. F., et al.
Publicado: (2017)

Striking Similarities between CDRs in Some mAbs That Neutralize COVID-19
por: Mi, Tianxiong, et al.
Publicado: (2020)

Potently neutralizing human mAbs against the zoonotic pararubulavirus Sosuga virus
por: Parrington, Helen M., et al.
Publicado: (2023)

P04-06. Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization
por: Gray, E, et al.
Publicado: (2009)

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

Chimeric Rhinoviruses Displaying MPER Epitopes Elicit Anti-HIV Neutralizing Responses
por: Yi, Guohua, et al.
Publicado: (2013)

The Different Colors of mAbs in Solution
por: Ambrogelly, Alexandre
Publicado: (2021)

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

Multimeric Scaffolds Displaying the HIV-1 Envelope MPER Induce MPER-Specific Antibodies and Cross-Neutralizing Antibodies when Co-Immunized with gp160 DNA
por: Krebs, Shelly J., et al.
Publicado: (2014)

Refined identification of neutralization-resistant CRF02_AG viruses and their sensitivity to anti-MPER neutralizing antibodies
por: Jacob, RA, et al.
Publicado: (2012)

Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2
por: Passariello, Margherita, et al.
Publicado: (2021)

Correction: Multimeric Scaffolds Displaying the HIV-1 Envelope MPER Induce MPER-Specific Antibodies and Cross-Neutralizing Antibodies when Co-Immunized with gp160 DNA
Publicado: (2015)

MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1
por: Ruprecht, Claudia R., et al.
Publicado: (2011)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Correction: Chimeric Rhinoviruses Displaying MPER Epitopes Elicit Anti-HIV Neutralizing Responses
por: Yi, Guohua, et al.
Publicado: (2013)

An MPER antibody neutralizes HIV-1 using germline features shared among donors
por: Zhang, Lei, et al.
Publicado: (2019)

Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01
por: Pinto, Dora, et al.
Publicado: (2019)

Cellular tools for biosimilar mAb analysis
por: Lindemann, Carsten, et al.
Publicado: (2013)

Evolving trends in mAb production processes
por: Shukla, Abhinav A., et al.
Publicado: (2017)

State of the art in anti-cancer mAbs
por: Chiavenna, S. M., et al.
Publicado: (2017)

Human neutralizing mAbs against Middle East respiratory syndrome coronavirus (MERS-CoV)
Publicado: (2014)

SCN-AVP release of mPer1/mPer2 double-mutant mice in vitro
por: van der Veen, Daan R, et al.
Publicado: (2008)

Retraction: eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2014)

OA021-04. HIV-1 gp41 envelope MPER mutation altered epitope conformation in lipid and increased sensitivity to 2F5 and 4E10 neutralizing antibodies
por: Shen, X, et al.
Publicado: (2009)

A Low Affinity GCaMP3 Variant (GCaMPer) for Imaging the Endoplasmic Reticulum Calcium Store
por: Henderson, Mark J., et al.
Publicado: (2015)

A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
por: Noy-Porat, Tal, et al.
Publicado: (2020)

Endothelial eNAMPT drives EndMT and preclinical PH: rescue by an eNAMPT-neutralizing mAb
por: Ahmed, Mohamed, et al.
Publicado: (2021)

Dynamics of SARS-CoV-2 VOC Neutralization and Novel mAb Reveal Protection against Omicron
por: Hao, Linhui, et al.
Publicado: (2023)

Stability enhancement in a mAb and Fab coformulation
por: Zhang, Hongyu, et al.
Publicado: (2020)

Pan-sarbecovirus mAb protects from variants
por: Flemming, Alexandra
Publicado: (2021)

A mAb for the detection of the antiretroviral drug emtricitabine
por: Youngpairoj, Ae S., et al.
Publicado: (2022)

Oxidation of specific tryptophan residues inhibits high-affinity binding of cocaine and its metabolites to a humanized anticocaine mAb
por: Kirley, Terence L., et al.
Publicado: (2022)

P19-50. Simulation of an MPER peptide samples epitope conformations of two broadly neutralizing antibodies
por: Wiehe, K, et al.
Publicado: (2009)

Antibody to gp41 MPER Alters Functional Properties of HIV-1 Env without Complete Neutralization
por: Kim, Arthur S., et al.
Publicado: (2014)

Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals
por: Molinos-Albert, Luis M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8mr81kgg71fu7338kmkvvvhkq2